VTR vs XENE · P/E 149, rev $1.73B vs $2.55B cap
Ventas Inc (VTR) versus Xenon Pharmaceuticals Inc (XENE) — a side-by-side from cached financials, not a winner call.
Ventas Inc (VTR) is a reit - healthcare facilities company listed on NYSE.
Xenon Pharmaceuticals Inc (XENE) is a biotechnology company listed on US.
Latest reported VTR revenue for 2026-06-30 was $1.73B. Net income was $72.2M. Revenue was up 4.4% from 2026-03-31 to 2026-06-30. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
Latest reported XENE revenue for 2026-06-30 was $0. Net income was -$213.0M. XENE currently screens at market cap $2.55B.
VTR currently screens at market cap $39.94B and trailing P/E 149.4. XENE currently screens at market cap $2.55B.
Not investment advice. Open the VTR and XENE stock pages for the full models.
Not investment advice.